{"disease":{"id":"immune-system-processes","name":"immune system processes"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01132859","title":"VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04837651","title":"Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab","phase":"","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Dragonfly Research, LLC","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}